UNLABELLED: By dual labeling a targeting moiety with both nuclear and optical probes, the ability for noninvasive imaging and intraoperative guidance may be possible. Herein, the ability to detect metastasis in an immunocompetent animal model of human epidermal growth factor receptor 2 (HER-2)-positive cancer metastases using positron emission tomography (PET) and near-infrared (NIR) fluorescence imaging is demonstrated. METHODS: ((64)Cu-DOTA)(n)-trastuzumab-(IRDye800)(m) was synthesized, characterized, and administered to female Balb/c mice subcutaneously inoculated with highly metastatic 4T1.2neu/R breast cancer cells. ((64)Cu-DOTA)(n)-trastuzumab-(IRDye800)(m) (150 µg, 150 µCi, m = 2, n = 2) was administered through the tail vein at weeks 2 and 6 after implantation, and PET/computed tomography and NIR fluorescence imaging were performed 24 hours later. Results were compared with the detection capabilities of F-18 fluorodeoxyglucose ((18)FDG-PET). RESULTS: Primary tumors were visualized with (18)FDG and ((64)Cu-DOTA)(n)-trastuzumab-(IRDye800)(m), but resulting metastases were identified only with the dual-labeled imaging agent. (64)Cu-PET imaging detected lung metastases, whereas ex vivo NIR fluorescence showed uptake in regions of lung, skin, skeletal muscle, and lymph nodes, which corresponded with the presence of cancer cells as confirmed by histologic hematoxylin and eosin stains. In addition to detecting the agent in lymph nodes, the high signal-to-noise ratio from NIR fluorescence imaging enabled visualization of channels between the primary tumor and the axillary lymph nodes, suggesting a lymphatic route for trafficking cancer cells. Because antibody clearance occurs through the liver, we could not distinguish between nonspecific uptake and liver metastases. CONCLUSION: ((64)Cu-DOTA)(n)-trastuzumab-(IRDye800)(m) may be an effective diagnostic imaging agent for staging HER-2-positive breast cancer patients and intraoperative resection.
UNLABELLED: By dual labeling a targeting moiety with both nuclear and optical probes, the ability for noninvasive imaging and intraoperative guidance may be possible. Herein, the ability to detect metastasis in an immunocompetent animal model of human epidermal growth factor receptor 2 (HER-2)-positive cancer metastases using positron emission tomography (PET) and near-infrared (NIR) fluorescence imaging is demonstrated. METHODS: ((64)Cu-DOTA)(n)-trastuzumab-(IRDye800)(m) was synthesized, characterized, and administered to female Balb/c mice subcutaneously inoculated with highly metastatic 4T1.2neu/R breast cancer cells. ((64)Cu-DOTA)(n)-trastuzumab-(IRDye800)(m) (150 µg, 150 µCi, m = 2, n = 2) was administered through the tail vein at weeks 2 and 6 after implantation, and PET/computed tomography and NIR fluorescence imaging were performed 24 hours later. Results were compared with the detection capabilities of F-18 fluorodeoxyglucose ((18)FDG-PET). RESULTS:Primary tumors were visualized with (18)FDG and ((64)Cu-DOTA)(n)-trastuzumab-(IRDye800)(m), but resulting metastases were identified only with the dual-labeled imaging agent. (64)Cu-PET imaging detected lung metastases, whereas ex vivo NIR fluorescence showed uptake in regions of lung, skin, skeletal muscle, and lymph nodes, which corresponded with the presence of cancer cells as confirmed by histologic hematoxylin and eosin stains. In addition to detecting the agent in lymph nodes, the high signal-to-noise ratio from NIR fluorescence imaging enabled visualization of channels between the primary tumor and the axillary lymph nodes, suggesting a lymphatic route for trafficking cancer cells. Because antibody clearance occurs through the liver, we could not distinguish between nonspecific uptake and liver metastases. CONCLUSION: ((64)Cu-DOTA)(n)-trastuzumab-(IRDye800)(m) may be an effective diagnostic imaging agent for staging HER-2-positive breast cancerpatients and intraoperative resection.
Authors: Emilia S Olson; Tao Jiang; Todd A Aguilera; Quyen T Nguyen; Lesley G Ellies; Miriam Scadeng; Roger Y Tsien Journal: Proc Natl Acad Sci U S A Date: 2010-02-16 Impact factor: 11.205
Authors: Ingrid Hilger; Yvonne Leistner; Alexander Berndt; Christine Fritsche; Karl Michael Haas; Hartwig Kosmehl; Werner A Kaiser Journal: Eur Radiol Date: 2004-04-30 Impact factor: 5.315
Authors: Heng Xu; Kwamena Baidoo; Andrew J Gunn; C Andrew Boswell; Diane E Milenic; Peter L Choyke; Martin W Brechbiel Journal: J Med Chem Date: 2007-08-29 Impact factor: 7.446
Authors: Lakshmi Sampath; Sunkuk Kwon; Shi Ke; Wei Wang; Rachel Schiff; Michel E Mawad; Eva M Sevick-Muraca Journal: J Nucl Med Date: 2007-09 Impact factor: 10.057
Authors: Y Ardeshirpour; V Chernomordik; J Capala; M Hassan; R Zielinsky; G Griffiths; S Achilefu; P Smith; A Gandjbakhche Journal: Technol Cancer Res Treat Date: 2011-12
Authors: Kenneth L Pinkston; Kavindra V Singh; Peng Gao; Nathaniel Wilganowski; Holly Robinson; Sukhen Ghosh; Ali Azhdarinia; Eva M Sevick-Muraca; Barbara E Murray; Barrett R Harvey Journal: Infect Immun Date: 2014-01-22 Impact factor: 3.441
Authors: Ruth Cohen; Danielle J Vugts; Marijke Stigter-van Walsum; Gerard W M Visser; Guus A M S van Dongen Journal: Nat Protoc Date: 2013-04-25 Impact factor: 13.491